Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction

Ki Young Lee

doi:10.4093/jkd.2011.12.4.190

Journal List > J Korean Diabetes > v.12(4) > 1054792

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee: Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction

Focused Issue

J Korean Diabetes 2011;12(4):190-193.

Published online: 22 January 2011

DOI: https://doi.org/10.4093/jkd.2011.12.4.190

Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction

Ki Young Lee

Devision of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University School of Medicine, Incheon, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The prevalence of type 2 diabetes mellitus in the Korea has increased dramatically over the past decade. Clinicians can prescribe the following six currently available classes of oral hypoglycemic agents: sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors and dipeptidyl peptidase inhibitors. The availability of various oral hypoglycemic agents has given rise to several adverse effects and may result in worse outcomes in patients with comorbid conditions such as liver dysfunction, renal impairment and heart failure. When taking a cross-sectional view of hepatic dysfunction, we find that hepatitis B and alcoholic liver disease are most prevalent in Korea. The use of oral hypoglycemic agents in type 2 diabetic patients with hepatic dysfunction requires many considerations.

Keywords: Type 2 diabetes mellitus, Liver diseases, Hypoglycemic agents, Oral administration

REFERENCES

1. Clementsen P, Hansen CL, H⊘egholm A. Glipizide induced toxic hepatitis. Ugeskr Laeger. 1986; 148:771–2.

2. Schneider HL, Hornbach KD, Kniaz JL, Efrusy ME. Chlorpropamide hepatotoxicity: report of a case and review of the literature. Am J Gastroenterol. 1984; 79:721–4.

3. Anderson RC, Harris PN, Worth HM. Toxicological studies on carbutamide. Diabetes. 1957; 6:2–7.

4. Goodman RC, Dean PJ, Radparvar A, Kitabchi AE. Glyburide-induced hepatitis. Ann Intern Med. 1987; 106:837–9.

5. Babich MM, Pike I, Shiffman ML. Metformin-induced acute hepatitis. Am J Med. 1998; 104:490–2.

6. Rocchi S, Auwerx J. Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator. Ann Med. 1999; 31:342–51.

7. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med. 1999; 16:179–92.

8. Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M, Yokoi T. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000; 30:61–70.

9. U.S. Food and Drug Administration. Zawadzki JK, Green L, Graham BJ. Thiazolidinedione-associated 15-month postmarketing hepatotoxicity. FDA Science Forum [Internet]. Silver Spring: U.S. Food and Drug Administration;2001. [cited 2002 Feb 5]. Available from:. http://www.accessdata.fda.gov/ScienceForums/forum02/AB-04.htm.

10. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med. 2000; 132:121–4.

11. Moore GA, Rossi L, Nicotera P, Orrenius S, O'Brien PJ. Quinone toxicity in hepatocytes: studies on mitochondrial Ca2+ release induced by benzoquinone derivatives. Arch Biochem Biophys. 1987; 259:283–95.

12. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001; 286:831–3.

13. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 1998; 129:36–8.

14. Elcock FJ, Lyon JJ, Hitchcock J, Morgan DG, Bertram TA, Bugelski PJ. Toxicity of troglitazone in cultured rat hepatocytes (abstract). Diabetes. 1999; 48(Suppl 1):A63.

15. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010; 12:648–58.

16. Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, Everhart JE, Moseley RH, Terrault N, Ackerson L, Selby JV. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med. 2003; 163:728–34.

17. Kwon SY. Current status of liver diseases in Korea: hepatitis A. Korean J Hepatol. 2009; 15(Suppl 6):S7–12.

18. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol. 2009; 15(Suppl 6):S13–24.

19. Lim YS. Current status of liver disease in Korea: hepatitis C. Korean J Hepatol. 2009; 15(Suppl 6):S25–8.

20. Kim KA. Current status of liver diseases in Korea: toxic and alcoholic liver diseases. Korean J Hepatol. 2009; 15(Suppl 6):S29–33.

21. Park SH. Current status of liver disease in Korea: nonalcoholic fatty liver disease. Korean J Hepatol. 2009; 15(Suppl 6):S34–9.

TOOLS

Similar articles